Navigation Links
New Drug Shows Significant Improvement In HIV-related Heart Condition

Latest research has shown that treatment with the oral drug bosentan (Tracleer) has led to significant improvements in an often fatal disease, pulmonary arterial hypertension ( PAH) // .

PAH is usually linked with human immunodeficiency virus infection. HIV infection is believed to cause the overproduction of endothelin, which increases the chance for small pulmonary arteries to become obstructed. This chronic obstruction leads to PAH, a condition that in most cases is the direct cause of death. Bosentan mediates the effects of excess endothelin production.

For the study 16 HIV-positive patients suffering from PAH who were treated with bosetan for 16 weeks were evaluated. Results showed there was significant improvement in survival indicators of the disease, such as six-minute walk distance and cardiac index, following bosetan treatment. However all patients suffered at least one adverse side effect of the drug including peripheral edema, headache, abnormal liver function, muscle cramps, fluid retention, and vomiting.
'"/>




Page: 1

Related medicine news :

1. Experimental treatment for Ebola Virus Shows promising results in mice
2. New Prostate Cancer Vaccine Shows Promise
3. Ebola Treatment Shows Promise
4. Greek Study Shows Living In The Hills May Be Healthier
5. Research Shows Carbon Monoxide Prevents Inflammations
6. Latest Research Shows That Multivitamins Might Not Prevent Infections In All Elderly
7. Novartis MS Drug Shows Promising Results
8. MRI Shows Emotional Changes During Menstrual Cycle
9. Bronchiolo-alveolar Carcinoma Shows Sonographic Pattern Of Pneumonia
10. AIDS drug GS 9137 Shows Promise
11. Teenager Shows Signs Of Recovery after Receiving Massive Dose of Radiation
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2017)... ... 2017 , ... The National Campaign to Prevent Teen ... to Contraception for Women Servicemembers and Dependents Act of 2017. The bill, introduced ... to ensure that all members of the Armed Forces receive high quality education ...
(Date:4/28/2017)... ... April 28, 2017 , ... Horizon Blue Cross Blue Shield of ... rating of “A” and its outlook as “stable.” At the same time, the ratings ... fallen in recent years, dip below “capital adequacy” thresholds required for its strong rating. ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... The ... board members and officers for 2017-2018. The annual board election process has been in ... a volunteer basis. , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, MHA, CMM, ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... or hERG liability could substantially improve drug safety and minimize the cost of ... for validating ion channel inhibition using cell lines and for cardiac toxicity using ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... for the North East region. Côté has 20+ years of experience within the ... Phytomer, Côté worked with an array of high-end cosmetic brands, retail brands and ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 2017 Global Prostate Cancer Therapeutics Market: ... prostate cancer therapeutics market analyzes the current and ... of prostate cancer, launch of promising emerging therapies, ... new drugs & therapeutic biological products, and high ... lesser side effects are some of the drivers ...
(Date:4/19/2017)... , April 19, 2017 The Global ... Forecast to 2022 report has covered and analysed the potential ... information on market size, shares and growth factors. The report ... challenges and opportunities in the global market. ... Browse 152 Tables and Figures, 6 Major ...
(Date:4/19/2017)... April 19, 2017 ... immune response in pets such as canine, avian ... of various types such as Attenuated Live Vaccines, ... DNA Vaccines and Recombinant Vaccines. Attenuated live vaccines ... or bacteria, which have been weakend under laboratory ...
Breaking Medicine Technology: